Agilent Technologies, Inc. - Diagnostics and Genomics SureSelectXT NCC oncopanel, 96 rxn auto
The SureSelectXT NCC Oncopanel, 96 rxn auto, from Agilent Technologies, is a targeted next-generation sequencing (NGS) solution designed for comprehensive cancer research. This panel enables the detection of key somatic mutations across a wide range of cancer-related genes, supporting high-throughput workflows with automation compatibility. The kit includes reagents for 96 reactions and is optimized for efficient hybrid capture, providing high sensitivity and specificity for variant detection in formalin-fixed, paraffin-embedded (FFPE) and fresh samples. It is intended for research use only and not for diagnostic procedures.